BACKGROUND Metal-on-metal(MoM)total hip arthroplasty(THA)has been associated with adverse reactions to metal debris,presenting clinically as pseudotumors.CASE SUMMARY This case report presents a female aged 73 year-ol...BACKGROUND Metal-on-metal(MoM)total hip arthroplasty(THA)has been associated with adverse reactions to metal debris,presenting clinically as pseudotumors.CASE SUMMARY This case report presents a female aged 73 year-old with MoM THA-related pseudotumor.After arthrotomy and bursectomy surgeries,histologic examinations of surgical specimens revealed a specific lymphocyte-dominant immunologic response,now known as aseptic lymphocyte-dominant vasculitisassociated lesion(ALVAL).Due to soft tissue persisting effusion after arthrotomy and bursectomy,revision surgery was then performed with ceramic-onpolyethylene THA.However,revision did not resolve the patient’s symptoms.Here we describe our application of tigecycline sclerotherapy to treat recurrent pseudotumor after revision THA and no recurrence after 24-mo follow-up.CONCLUSION Tigecycline sclerotherapy is safe and effective in the management of recurrent pseudotumor after revision non-MoM THA in ALVAL cases.展开更多
文摘BACKGROUND Metal-on-metal(MoM)total hip arthroplasty(THA)has been associated with adverse reactions to metal debris,presenting clinically as pseudotumors.CASE SUMMARY This case report presents a female aged 73 year-old with MoM THA-related pseudotumor.After arthrotomy and bursectomy surgeries,histologic examinations of surgical specimens revealed a specific lymphocyte-dominant immunologic response,now known as aseptic lymphocyte-dominant vasculitisassociated lesion(ALVAL).Due to soft tissue persisting effusion after arthrotomy and bursectomy,revision surgery was then performed with ceramic-onpolyethylene THA.However,revision did not resolve the patient’s symptoms.Here we describe our application of tigecycline sclerotherapy to treat recurrent pseudotumor after revision THA and no recurrence after 24-mo follow-up.CONCLUSION Tigecycline sclerotherapy is safe and effective in the management of recurrent pseudotumor after revision non-MoM THA in ALVAL cases.
